Open AccessUsefulness of population pharmacokinetics to optimize the dosage regimen of infliximab in inflammatory bowel disease patients
Author(s) -
M Gil Candel,
Juan José Gascón Cánovas,
Rosa Gómez Espín,
Isabel Nicolás de Prado,
Lorena Rentero Redondo,
E Urbieta Sanz,
Carles Iniesta Navalón
Publication year - 2020
Publication title -
revista española de enfermedades digestivas/revista española de enfermedades digestivas
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.331
H-Index - 38
eISSN - 2340-4167
pISSN - 1130-0108
DOI - 10.17235/reed.2020.6857/2020
Subject(s) - medicine , infliximab , nonmem , inflammatory bowel disease , dosing , therapeutic drug monitoring , trough concentration , population , regimen , trough level , gastroenterology , pharmacokinetics , disease , surgery , transplantation , environmental health , tacrolimus
infliximab is used in inflammatory bowel disease, which has a great inter-individual pharmacokinetic variability. Thus, it is necessary to individualize the therapy in many cases. The main objective of our study was to compare two methods of a dose adjustment strategy using therapeutic drug monitoring: a) based on an algorithm and b) based on Bayesian prediction, to achieve an optimal infliximab trough level in patients with inflammatory bowel diseases. The secondary objective was to evaluate the predictive performance of a population pharmacokinetic model of infliximab in patients with inflammatory bowel diseases and therefore, its clinical utility. Furthermore, the factors associated with a suboptimal adjustment of the model were analyzed.